title: [Heparin-induced thrombopenia].
abstract: Heparin-induced thrombocytopenia remains a topical subject for at least two reasons. The first reason is the increasing prescription of low molecular weight heparins (LMWH) rather than unfractionated heparins, with limited laboratory surveillance, raising the question concerning the need for twice-weekly platelet counts, according to the recommendations of the Vidal drug directory. The second reason is the recent release onto the market of two products, danaparoid (Orgaran) and lepirudin (Refludin) for this precise indication of heparin-induced thrombocytopenia. These products greatly facilitate the management of this complication. Many basic research teams are trying to optimize the detection of heparin-dependent antibodies and to more clearly elucidate the mechanism of this particular thrombocytopenia, which carries a risk of very severe thrombotic complications when the diagnosis is delayed.
authors.affiliation: Laboratoire d'Hématologie-Hémostase, Centre Hospitalier et Universitaire, 54000 Nancy.
authors.forename: E
authors.initials: E
authors.lastname: de Maistre
authors.forename: D
authors.initials: D
authors.lastname: Wahl
authors.forename: M E
authors.initials: ME
authors.lastname: Briquel
authors.forename: E
authors.initials: E
authors.lastname: André
authors.forename: T
authors.initials: T
authors.lastname: Lecompte
mesh_terms: D000906:Antibodies / Q000097:blood; D000925:Anticoagulants / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D003871:Dermatan Sulfate / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods / Q000592:standards; D004363:Drug Utilization; D004797:Enzyme-Linked Immunosorbent Assay; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D006497:Heparan Sulfate / Q000627:therapeutic use; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D016209:Interleukin-8 / Q000097:blood; D010455:Peptides / Q000097:blood; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000378:metabolism; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control; D013997:Time Factors; D001620:beta-Thromboglobulin
chemical_list: D000906:Antibodies; D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006493:Heparin; D006497:Heparan Sulfate; D006629:Hirudins; D016209:Interleukin-8; D010455:Peptides; D010978:Platelet Factor 4; D011994:Recombinant Proteins; D001620:beta-Thromboglobulin; C061615:PPBP protein, human; C035838:danaparoid; C083544:lepirudin